{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T01:55:16Z","timestamp":1778291716653,"version":"3.51.4"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,4,5]],"date-time":"2019-04-05T00:00:00Z","timestamp":1554422400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Tainan Municipal Hospital (managed by Show Chwan Medical Care Corporation), Tainan, Taiwan","award":["106-2"],"award-info":[{"award-number":["106-2"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Endocr Disord"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s12902-019-0362-7","type":"journal-article","created":{"date-parts":[[2019,4,5]],"date-time":"2019-04-05T13:03:08Z","timestamp":1554469388000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Long-term outcomes and risk factors of thyroid dysfunction during pegylated interferon and ribavirin treatment in patients with chronic hepatitis C infection in Taiwan"],"prefix":"10.1186","volume":"19","author":[{"given":"Yu-Kang","family":"Chang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuan-Tsung","family":"Tseng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kou-Huang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kow-Tong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,4,5]]},"reference":[{"key":"362_CR1","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1046\/j.1365-2893.1999.6120139.x","volume":"6","author":"World Health Organization","year":"1999","unstructured":"World Health Organization. Global surveillance and control of hepatitis C. Report of a WHO consultation organised in collaboration with the viral hepatitis prevention board, Antwerp, Belgium. J Viral Hepat. 1999;6:35\u201347.","journal-title":"J Viral Hepat"},{"key":"362_CR2","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/S0168-8278(99)80239-6","volume":"31","author":"AL Zignego","year":"1999","unstructured":"Zignego AL, Brechot C. Extrahepatic manifestations of HCV infection: facts and controversies. J Hepatol. 1999;31:369\u201376.","journal-title":"J Hepatol"},{"key":"362_CR3","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/S0168-8278(99)80367-5","volume":"31","author":"EASL (European Association on the studies on the Liver)","year":"1999","unstructured":"EASL (European Association on the studies on the Liver). EASL international consensus conference on hepatitis C. Paris, 26\u201327 February 1999. Consensus statement. J Hepatol. 1999;31:3\u20138.","journal-title":"J Hepatol"},{"key":"362_CR4","doi-asserted-by":"publisher","first-page":"97","DOI":"10.5582\/bst.2015.01033","volume":"9","author":"M Zhou","year":"2015","unstructured":"Zhou M, Li H, Ji Y, Ma Y, Hou F, Yuan P. Hepatitis C virus infection in the general population: a large community-based study in Mianyang, West China. Biosci Trends. 2015;9:97\u2013103.","journal-title":"Biosci Trends"},{"key":"362_CR5","doi-asserted-by":"publisher","first-page":"76","DOI":"10.3350\/cmh.2016.22.1.76","volume":"22","author":"Korean Association for the Study of the Liver","year":"2016","unstructured":"Korean Association for the Study of the Liver. KASL clinical practice guidelines: management of hepatitis C. Clin Mol Hepatol. 2016;22:76\u2013139.","journal-title":"Clin Mol Hepatol"},{"key":"362_CR6","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1080\/14787210.2017.1354697","volume":"15","author":"ML Polo","year":"2017","unstructured":"Polo ML, Laufer N. Extrahepatic manifestations of HCV: the role of direct acting antivirals. Expert Rev Anti-Infect Ther. 2017;15:737\u201346.","journal-title":"Expert Rev Anti-Infect Ther"},{"key":"362_CR7","doi-asserted-by":"crossref","first-page":"227","DOI":"10.15403\/jgld.2014.1121.252.chc","volume":"25","author":"Y Shen","year":"2016","unstructured":"Shen Y, Wang XL, Xie JP, Shao JG, Lu YH, Zhang S, Qin G. Thyroid disturbance in patients with chronic hepatitis C infection: a systematic review and meta-analysis. J Gastrointestin Liver Dis. 2016;25:227\u201334.","journal-title":"J Gastrointestin Liver Dis"},{"key":"362_CR8","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1046\/j.1365-2265.1999.00686.x","volume":"50","author":"MJ Huang","year":"1999","unstructured":"Huang MJ, Tsai SL, Huang BY, Sheen IS, Yeh CT, Liaw YF. Prevalence and significance of thyroid autoantibodies in patients with chronic hepatitis C virus infection: a prospective controlled study. Clin Endocrinol. 1999;50:503\u20139.","journal-title":"Clin Endocrinol"},{"key":"362_CR9","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1016\/j.ecl.2007.07.001","volume":"36","author":"Y Tomer","year":"2007","unstructured":"Tomer Y, Blackard JT, Akeno N. Interferon alpha treatment and thyroid dysfunction. Endocrinol Metabol Clin North Am. 2007;36:1051\u201366.","journal-title":"Endocrinol Metabol Clin North Am"},{"key":"362_CR10","doi-asserted-by":"publisher","first-page":"977","DOI":"10.2174\/1381612024607018","volume":"8","author":"A Ascione","year":"2002","unstructured":"Ascione A, De Luca M, Di Costanzo GG, et al. Incidence of side effects during therapy with different types of alpha interferon: a randomised controlled trial comparing recombinant alpha 2b versus leukocyte interferon in the therapy of naive patients with chronic hepatitis C. Curr Pharm Des. 2002;8:977\u201380.","journal-title":"Curr Pharm Des"},{"key":"362_CR11","doi-asserted-by":"publisher","first-page":"2381","DOI":"10.1099\/0022-1317-79-10-2381","volume":"79","author":"C Hultgren","year":"1998","unstructured":"Hultgren C, Milich DR, Weiland O, Sallberg M. The antiviral compound ribavirin modulates the T helper (Th)1\/Th2 subset balance in hepatitis B and C virus-specific immune responses. J Gen Virol. 1998;79:2381\u201391.","journal-title":"J Gen Virol"},{"key":"362_CR12","doi-asserted-by":"publisher","first-page":"3656","DOI":"10.1210\/jc.2004-0627","volume":"89","author":"C Carella","year":"2004","unstructured":"Carella C, Mazziotti G, Amato G, Braverman LE, Roti E. Clinical review 169: interferon alpha related thyroid disease: pathophysiological, epidemiological and clinical aspects. J Clin Endocrinol Metab. 2004;89:3656\u201361.","journal-title":"J Clin Endocrinol Metab"},{"key":"362_CR13","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1111\/j.1440-1746.2009.05874.x","volume":"24","author":"HA Trans","year":"2009","unstructured":"Trans HA, Reeves GEM, Gibson R, Attia JR. Development of thyroid diseases in the treatment of chronic hepatitis C with a interferon may be a good prognosticator in achieving a sustained virological response: a meta-analysis. J Gastroenterol Hepatol. 2009;24:1163\u20138.","journal-title":"J Gastroenterol Hepatol"},{"key":"362_CR14","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1016\/S0016-5085(03)00394-9","volume":"124","author":"MW Russo","year":"2003","unstructured":"Russo MW, Fried MW. Side effects of therapy for chronic hepatitis C. Gastroenterology. 2003;124:1711\u20139.","journal-title":"Gastroenterology"},{"key":"362_CR15","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/S0168-8278(96)80184-X","volume":"24","author":"G Fattovich","year":"1996","unstructured":"Fattovich G, Giustina G, Favarato S, Ruol A. A survey of adverse events in 11,241 patients with chronic viral hepatitis treated with a interferon. J Hepatol. 1996;24:38\u201347.","journal-title":"J Hepatol"},{"key":"362_CR16","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1053\/hupa.2001.28228","volume":"32","author":"H Fontaine","year":"2001","unstructured":"Fontaine H, Nalpas B, Poulet B, Carnot F, Zylberberg H, Brechot C, Pol S. Hepatitis activity index is a key factor in determining the natural history of chronic hepatitis C. Hum Pathol. 2001;32:904\u20139.","journal-title":"Hum Pathol"},{"key":"362_CR17","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1136\/gut.2005.076646","volume":"55","author":"MP Manns","year":"2006","unstructured":"Manns MP, Wedemeyer H, Cornberg M. Treating viral hepatitis C: efficacy, side effects and complications. Gut. 2006;55:1350\u20139.","journal-title":"Gut"},{"key":"362_CR18","doi-asserted-by":"publisher","first-page":"2470","DOI":"10.4049\/jimmunol.168.5.2470","volume":"168","author":"SH Wang","year":"2002","unstructured":"Wang SH, Bretz JD, Phelps E, et al. A unique combination of inflammatory cytokines enhances apoptosis of thyroid follicular cells and transforms nondestructive to destructive thyroiditis in experimental autoimmune thyroiditis. J Immunol. 2002;168:2470\u20134.","journal-title":"J Immunol"},{"key":"362_CR19","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1016\/S0002-9343(96)00259-8","volume":"101","author":"E Roti","year":"1996","unstructured":"Roti E, Minelli R, Giuberti T, et al. Multiple changes in thyroid function in patients with chronic active HCV hepatitis treated with recombinant interferon-alpha. Am J Med. 1996;101:482\u20137.","journal-title":"Am J Med"},{"key":"362_CR20","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1007\/s12072-015-9629-x","volume":"9","author":"H Bennett","year":"2015","unstructured":"Bennett H, Waser N, Johnston K, et al. A review of the burden of hepatitis C virus infection in China, Japan, South Korea and Taiwan. Hepatol Int. 2015;9:378\u201390.","journal-title":"Hepatol Int"},{"key":"362_CR21","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1086\/592579","volume":"47","author":"CH Liu","year":"2008","unstructured":"Liu CH, Liu CJ, Lin CL, et al. Pegylated interferon-alpha-2a plus ribavirin for treatment-naive Asian patients with hepatitis C virus genotype 1 infection: a multicenter, randomized controlled trial. Clin Infect Dis. 2008;47:1260\u20139.","journal-title":"Clin Infect Dis"},{"key":"362_CR22","doi-asserted-by":"publisher","first-page":"e6984","DOI":"10.1097\/MD.0000000000006984","volume":"96","author":"PC Tsai","year":"2007","unstructured":"Tsai PC, Liu TW, Tsai YS, et al. Identification of groups with poor cost effectiveness of peginterferon plus ribavirin for na\u00efve hepatitis C patients with a real-world cohort and database. Medicine (Baltimore). 2007;96:e6984.","journal-title":"Medicine (Baltimore)"},{"key":"362_CR23","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/S2468-1253(16)30080-2","volume":"2","author":"SG Lim","year":"2017","unstructured":"Lim SG, Aghemo A, Chen PJ, et al. Management of hepatitis C virus infection in the Asia-Pacific region: an update. Lancet Gastroenterol Hepatol. 2017;2:52\u201362.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"362_CR24","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1111\/j.1469-0691.2009.02937.x","volume":"16","author":"HH Lin","year":"2010","unstructured":"Lin HH, Hsu KL, Ko WW, et al. Cost-effectiveness of influenza immunization in adult cancer patients in Taiwan. Clin Microbiol Infect. 2010;16:663\u201370.","journal-title":"Clin Microbiol Infect"},{"key":"362_CR25","unstructured":"Bureau of National Health Insurance, Taiwan. The National Health Insurance Annual Statistical Report, 2001-2013. Accessed 15 Aug 2017 by https:\/\/www.nhi.gov.tw\/english\/Content_List.aspx?n=616B97F8DF2C3614&topn=616B97F8DF2C3614 ."},{"key":"362_CR26","unstructured":"ICD-9 CM easy coder. Volume 3. Montgomery, A.L. Unicor Medical, Inc., 2002."},{"key":"362_CR27","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1111\/j.1440-1746.2006.04771.x","volume":"22","author":"HA Tran","year":"2007","unstructured":"Tran HA, Attia JR, Jones TL, Batey RG. Pegylated interferon-alpha2beta in combination with ribavirin does not aggravate thyroid dysfunction in comparison to regular interferon-alpha2beta in a hepatitis C population: meta-analysis. J Gastroenterol Hepatol. 2007;22:472\u20136.","journal-title":"J Gastroenterol Hepatol"},{"key":"362_CR28","doi-asserted-by":"publisher","first-page":"792","DOI":"10.3904\/kjim.2015.30.6.792","volume":"30","author":"Y Hwang","year":"2015","unstructured":"Hwang Y, Kim W, Kwon SY, Yu HM, Kim JH, Choe WH. Incidence of and risk factors for thyroid dysfunction during peginterferon \u03b1 and ribavirin treatment in patients with chronic hepatitis C. Korean J Intern Med. 2015;30:792\u2013800.","journal-title":"Korean J Intern Med."},{"key":"362_CR29","first-page":"555","volume":"71","author":"D Kozielewicz","year":"2017","unstructured":"Kozielewicz D, Wietlicka-Piszcz M, Halota W. Long-term outcomes of thyroid dysfunction in patients with chronic hepatitis C treated with pegylated interferon alpha and ribavirin. Przegl Epidemiol. 2017;71:555\u201369.","journal-title":"Przegl Epidemiol"},{"key":"362_CR30","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1186\/s12872-016-0300-9","volume":"16","author":"M Cybulsky","year":"2016","unstructured":"Cybulsky M, Cook S, Kontsevaya AV, Vasiljev M, Leon DA. Pharmacological treatment of hypertension and hyperlipidemia in Izhevsk, Russia. BMC Cardiovasc Disord. 2016;16:122.","journal-title":"BMC Cardiovasc Disord"},{"key":"362_CR31","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","volume":"34","author":"DR Cox","year":"1972","unstructured":"Cox DR. Regression models and life tables. J R Stat Soc Series B Stat Methodol. 1972;34:187\u2013220.","journal-title":"J R Stat Soc Series B Stat Methodol"},{"key":"362_CR32","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1111\/j.1440-1746.2008.05690.x","volume":"24","author":"KM Jamil","year":"2009","unstructured":"Jamil KM, Leedman PJ, Kontorinis N, et al. Interferon-induced thyroid dysfunction in chronic hepatitis C. J Gastroenterol Hepatol. 2009;24:1017\u201323.","journal-title":"J Gastroenterol Hepatol"},{"key":"362_CR33","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.jfma.2015.06.012","volume":"115","author":"JH Kao","year":"2016","unstructured":"Kao JH. Hepatitis C virus infection in Taiwan: past, present, and future. J Formos Med Assoc. 2016;115:65\u20136.","journal-title":"J Formos Med Assoc"},{"key":"362_CR34","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1530\/eje.0.1460743","volume":"146","author":"C Carella","year":"2002","unstructured":"Carella C, Mazziotti G, Morisco F, et al. The addition of ribavirin to interferon-alpha therapy in patients with hepatitis C virus-related chronic hepatitis does not modify the thyroid autoantibody pattern but increases the risk of developing hypothyroidism. Eur J Endocrinol. 2002;146:743\u20139.","journal-title":"Eur J Endocrinol"},{"key":"362_CR35","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1046\/j.1365-2265.1996.751768.x","volume":"44","author":"M Marazuela","year":"1996","unstructured":"Marazuela M, Garcia-Buey L, Gonzalez-Fernandez B, et al. Thyroid autoimmune disorders in patients with chronic hepatitis C before and during interferon-alpha therapy. Clin Endocrinol. 1996;44:635\u201342.","journal-title":"Clin Endocrinol"},{"key":"362_CR36","doi-asserted-by":"publisher","first-page":"980942","DOI":"10.1155\/2012\/980942","volume":"2012","author":"AL Zignego","year":"2012","unstructured":"Zignego AL, Giannini C, Gragnani L. HCV and lymphoproliferation. Clin Dev Immunol. 2012;2012:980942.","journal-title":"Clin Dev Immunol"},{"key":"362_CR37","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1089\/jir.2011.0101","volume":"31","author":"D Choubey","year":"2011","unstructured":"Choubey D, Moudgil KD. Interferons in autoimmune and inflammatory diseases: regulation and roles. J Interf Cytokine Res. 2011;31:857\u201365.","journal-title":"J Interf Cytokine Res"},{"key":"362_CR38","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1002\/hep.1840180205","volume":"18","author":"A Tran","year":"1993","unstructured":"Tran A, Quaranta JF, Benzaken S, et al. High prevalence of thyroid autoantibodies in a prospective series of patients with chronic hepatitis C before interferon therapy. Hepatology. 1993;18:253\u20137.","journal-title":"Hepatology"},{"key":"362_CR39","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1089\/thy.2006.16.563","volume":"16","author":"A Antonelli","year":"2006","unstructured":"Antonelli A, Ferri C, Fallahi P, et al. Thyroid disorders in chronic hepatitis C virus infection. Thyroid. 2006;16:563\u201372.","journal-title":"Thyroid."},{"key":"362_CR40","first-page":"61","volume":"23","author":"H Mu\u00f1oz","year":"2004","unstructured":"Mu\u00f1oz H, Arroyo J, Torres EA, et al. Response to combination therapy of interferon alfa-2b plus ribavirin in Hispanics with chronic hepatitis C. P. R. Health Sci J. 2004;23:61\u20137.","journal-title":"Health Sci J"},{"key":"362_CR41","doi-asserted-by":"publisher","first-page":"346","DOI":"10.7326\/0003-4819-140-5-200403020-00010","volume":"140","author":"SJ Hadziyannis","year":"2004","unstructured":"Hadziyannis SJ, Sette H Jr, Morgan TR, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med. 2004;140:346\u201355.","journal-title":"Ann Intern Med"},{"key":"362_CR42","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1136\/gut.52.3.425","volume":"52","author":"U Siebert","year":"2003","unstructured":"Siebert U, Sroczynski G, Rossol S, et al. German Hepatitis C Model (GEHMO) Group; International Hepatitis Interventional Therapy (IHIT) Group. Cost effectiveness of peginterferon alpha-2b plus ribavirin versus interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C. Gut. 2003;52:425\u201332.","journal-title":"Gut."},{"key":"362_CR43","doi-asserted-by":"publisher","first-page":"e55364","DOI":"10.1371\/journal.pone.0055364","volume":"8","author":"C Nair Kesavachandran","year":"2013","unstructured":"Nair Kesavachandran C, Haamann F, Nienhaus A. Frequency of thyroid dysfunctions during interferon alpha treatment of single and combination therapy in hepatitis C virus-infected patients: a systematic review based analysis. PLoS One. 2013;8:e55364.","journal-title":"PLoS One"},{"key":"362_CR44","doi-asserted-by":"publisher","first-page":"792","DOI":"10.3904\/kjim.2015.30.6.792","volume":"30","author":"Y Hwang","year":"2015","unstructured":"Hwang Y, Kim W, Kwon SY, Yu HM, Kim JH, Choe WH. Incidence of and risk factors for thyroid dysfunction during peginterferon \u03b1and ribavirin treatment in patients with chronic hepatitis C. Korean J Intern Med. 2015;30:792\u2013800.","journal-title":"Korean J Intern Med"},{"key":"362_CR45","volume":"12","author":"Z Yan","year":"2012","unstructured":"Yan Z, Fan K, Fan Y, et al. Thyroid dysfunction in Chinese patients with chronic hepatitis C treated with interferon alpha: incidence, long-term outcome and predictive factors. Hepat Mon. 2012;12:e6390.","journal-title":"Hepat Mon"},{"key":"362_CR46","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/ncpendmet1027","volume":"5","author":"A Antonelli","year":"2009","unstructured":"Antonelli A, Ferri C, Ferrari SM, Colaci M, Sansonno D, Fallahi P. Endocrine manifestations of hepatitis C virus infection. Nat Clin Pract Endocrinol Metab. 2009;5:26\u201334.","journal-title":"Nat Clin Pract Endocrinol Metab"},{"key":"362_CR47","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.amjmed.2004.01.023","volume":"117","author":"A Antonelli","year":"2004","unstructured":"Antonelli A, Ferri C, Pampana A, et al. Thyroid disorders in chronic hepatitis C. Am J Med. 2004;117:10\u20133.","journal-title":"Am J Med"},{"key":"362_CR48","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1089\/105072503322238809","volume":"13","author":"MF Prummel","year":"2003","unstructured":"Prummel MF, Laurberg P. Interferon-alpha and autoimmune thyroid disease. Thyroid. 2003;13:547\u201351.","journal-title":"Thyroid."},{"key":"362_CR49","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.ejim.2016.12.015","volume":"38","author":"AP Delitala","year":"2017","unstructured":"Delitala AP, Fanciulli G, Maioli M, Delitala G. Subclinical hypothyroidism, lipid metabolism and cardiovascular disease. Eur J Intern Med. 2017;38:17\u201324.","journal-title":"Eur J Intern Med"},{"key":"362_CR50","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/952729","volume":"2015","author":"DO Yetkin","year":"2015","unstructured":"Yetkin DO, Dogantekin B. The lipid parameters and lipoprotein(a) excess in Hashimoto thyroiditis. Int J Endocrinol. 2015;2015:952729.","journal-title":"Int J Endocrinol"},{"key":"362_CR51","doi-asserted-by":"publisher","first-page":"500","DOI":"10.14310\/horm.2002.1707","volume":"15","author":"LH Duntas","year":"2016","unstructured":"Duntas LH, Brenta G. Thyroid hormones: a potential ally to LDL-cholesterol-lowering agents. Hormones (Athens). 2016;15:500\u201310.","journal-title":"Hormones (Athens)"},{"key":"362_CR52","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1111\/jgh.12313","volume":"30","author":"CY Dai","year":"2015","unstructured":"Dai CY, Yeh ML, Huang CF, et al. Chronic hepatitis C infection is associated with insulin resistance and lipid profiles. J Gastroenterol Hepatol. 2015;30:879\u201384.","journal-title":"J Gastroenterol Hepatol"},{"key":"362_CR53","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1111\/j.1365-2893.2005.00655.x","volume":"3","author":"D Siagris","year":"2006","unstructured":"Siagris D, Christofidou M, Theocharis GJ, et al. Serum lipid pattern in chronic hepatitis C: histological and virological correlations. J Viral Hepat. 2006;3:56\u201361.","journal-title":"J Viral Hepat"},{"key":"362_CR54","doi-asserted-by":"publisher","first-page":"21313","DOI":"10.18632\/oncotarget.25092","volume":"9","author":"B Batsaikhan","year":"2018","unstructured":"Batsaikhan B, Huang CI, Yeh ML, et al. The effect of antiviral therapy on serum lipid profiles in chronic hepatitis C. Oncotarget. 2018;9:21313\u201321.","journal-title":"Oncotarget."},{"key":"362_CR55","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.mcna.2012.01.012","volume":"96","author":"LH Duntas","year":"2012","unstructured":"Duntas LH, Brenta G. The effect of thyroid disorders on lipid levels and metabolism. Med Clin North Am. 2012;96:269\u201381.","journal-title":"Med Clin North Am"},{"key":"362_CR56","doi-asserted-by":"publisher","first-page":"338","DOI":"10.7326\/0003-4819-68-2-338","volume":"68","author":"AD Steinberg","year":"1968","unstructured":"Steinberg AD. Myxedema and coronary artery disease--a comparative autopsy study. Ann Intern Med. 1968;68:338\u201344.","journal-title":"Ann Intern Med"},{"key":"362_CR57","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1007\/s12020-017-1373-7","volume":"57","author":"HS Huang","year":"2017","unstructured":"Huang HS, Lee KW, Ho CH, et al. Increased risk for hypothyroidism after anticholinesterase pesticide poisoning: a nationwide population-based study. Endocrine. 2017;57:436\u201344.","journal-title":"Endocrine."}],"container-title":["BMC Endocrine Disorders"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12902-019-0362-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12902-019-0362-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12902-019-0362-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,16]],"date-time":"2024-07-16T17:02:47Z","timestamp":1721149367000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcendocrdisord.biomedcentral.com\/articles\/10.1186\/s12902-019-0362-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,5]]},"references-count":57,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["362"],"URL":"https:\/\/doi.org\/10.1186\/s12902-019-0362-7","relation":{},"ISSN":["1472-6823"],"issn-type":[{"value":"1472-6823","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,5]]},"assertion":[{"value":"9 May 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 April 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"In this study, we used the NHIR database. According to the regulation of Ministry of Health and Welfare, Taiwan, all of the NHIR datasets are only available from the information Center, Ministry of Health and Welfare, Taiwan. The study was approved by the Institute Review Board of the Show Chwan Memorial Hospital, Taiwan (No. 1051201). Informed consent from the subjects was not obtained because there was no personal contact between the patients and the data collectors.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"36"}}